{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:53:07Z","timestamp":1792849987134,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T00:00:00Z","timestamp":1608336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["825392"],"award-info":[{"award-number":["825392"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BU 2722\/2\\u20133"],"award-info":[{"award-number":["BU 2722\/2\\u20133"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 6880\/2\\u20133"],"award-info":[{"award-number":["HA 6880\/2\\u20133"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BU 2722\/2"],"award-info":[{"award-number":["BU 2722\/2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 6880\/2"],"award-info":[{"award-number":["HA 6880\/2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 6880\/2-1"],"award-info":[{"award-number":["HA 6880\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jaut.2020.102591","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T15:15:36Z","timestamp":1609341336000},"page":"102591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis"],"prefix":"10.1016","volume":"117","author":[{"given":"Laura Elisa","family":"Buitrago-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pietrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Noyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Schlue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-7787","authenticated-orcid":false,"given":"Matthias","family":"Hardtke-Wolenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Jaeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2020.102591_bib1","doi-asserted-by":"crossref","unstructured":"European association for the study of the, L., EASL clinical practice guidelines: Autoimmune hepatitis. J. Hepatol., 2015. 63(4): p. 971-1004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"issue":"6","key":"10.1016\/j.jaut.2020.102591_bib2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2020.102591_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaut.2016.07.005","article-title":"Cutting edge issues in autoimmune hepatitis","volume":"75","author":"Liberal","year":"2016","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.jaut.2020.102591_bib4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","article-title":"Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies","volume":"61","author":"Taubert","year":"2014","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102591_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jaut.2020.102591_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2018.06.006","article-title":"Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2","volume":"142","author":"Churlaud","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102591_bib7","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","article-title":"Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases","volume":"203","author":"Tahvildari","year":"2019","journal-title":"J. Immunol."},{"issue":"315","key":"10.1016\/j.jaut.2020.102591_bib8","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.jaut.2020.102591_bib9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/ajt.15700","article-title":"Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation","volume":"20","author":"Sanchez-Fueyo","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.jaut.2020.102591_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/tri.12998","article-title":"Regulatory T-cell therapy in liver transplantation","volume":"30","author":"Whitehouse","year":"2017","journal-title":"Transpl. Int."},{"issue":"2","key":"10.1016\/j.jaut.2020.102591_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/liv.14296","article-title":"Autoimmune hepatitis induction can occur in the liver","volume":"40","author":"Dywicki","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.jaut.2020.102591_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2016.12.001","article-title":"The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development","volume":"78","author":"Hardtke-Wolenski","year":"2017","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jaut.2020.102591_bib13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/hep.26380","article-title":"Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4(+) T cells","volume":"58","author":"Hardtke-Wolenski","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jaut.2020.102591_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.jaut.2020.102591_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2165\/00003495-199346030-00009","article-title":"Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer","volume":"46","author":"Whittington","year":"1993","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.jaut.2020.102591_bib16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.jaut.2020.102591_bib17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jaut.2020.102591_bib18","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low-dose interleukin-2 for refractory autoimmune hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jaut.2020.102591_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.12940","article-title":"Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases","volume":"188","author":"Jeffery","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2020.102591_bib20","first-page":"429","article-title":"Phase I\/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease","volume":"70","author":"Asano","year":"2016","journal-title":"Acta Med. Okayama"},{"key":"10.1016\/j.jaut.2020.102591_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.jaut.2020.102591_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002139","article-title":"Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial","volume":"13","author":"Todd","year":"2016","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.jaut.2020.102591_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"10.1016\/j.jaut.2020.102591_bib24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat. Med."},{"issue":"27","key":"10.1016\/j.jaut.2020.102591_bib25","doi-asserted-by":"crossref","first-page":"13508","DOI":"10.1073\/pnas.1903165116","article-title":"Treg-mediated prolonged survival of skin allografts without immunosuppression","volume":"116","author":"Pilat","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120302262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120302262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:45:25Z","timestamp":1778546725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841120302262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":25,"alternative-id":["S0896841120302262"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102591","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102591"}}